Academia Sinica Logo

This study, led by Drs. Yi-Ling Lin and Hui-Ying Ko at Academia Sinica, presents a novel Vectored ImmunoProphylaxis (VIP) strategy that employs adeno-associated virus (AAV)-mediated delivery of the broadly neutralizing human monoclonal antibody 752-2C8 to provide long-term protection against dengue and Zika virus infections. A single systemic administration of the recombinant AAV construct resulted in sustained in vivo antibody expression, reaching concentrations of approximately 1 mg/mL and remaining stable for at least 48 weeks. Importantly, this durable antibody response conferred complete protection against lethal challenges with all four dengue virus serotypes and Zika virus in a highly susceptible mouse model. These findings demonstrate the potential of VIP as an effective and long-lasting antiviral strategy, offering a promising alternative to traditional vaccines and passive immunization approaches. The work has published in Molecular Therapy (September 2025) and was supported by Academia Sinica and the National Science and Technology Council (NSTC) of Taiwan.